Related Experiment Video

Updated: Aug 2, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic

Long Li1,2,3, Shancheng He4,5,6

  • 1Department of Critical Care Medicine, The Fifth People's Hospital of Ganzhou City, Ganzhou, 341000, China.

Discover Oncology
|December 23, 2024
PubMed

Insights

Programmed cell death pathways like ferroptosis and pyroptosis are key to understanding lung adenocarcinoma (LUAD) heterogeneity and improving survival. Targeting these pathways may enhance anti-tumor immunity and immunotherapy response in LUAD patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Lung adenocarcinoma (LUAD) presents significant challenges due to tumor heterogeneity and drug resistance.
  • Programmed cell death (PCD) pathways play a critical role in cancer development and progression.

Purpose of the Study:

  • To investigate the role of PCD pathways (apoptosis, necroptosis, pyroptosis, ferroptosis) in LUAD heterogeneity, immune infiltration, and prognosis.
  • To identify LUAD subtypes based on PCD pathway activation and their clinical implications.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) was employed to analyze PCD pathway activation in LUAD.
  • Differential pathway activation and immune cell composition were assessed across identified LUAD subtypes.
  • Drug sensitivity analysis was performed to evaluate treatment responses.

Main Results:

  • Ferroptosis and pyroptosis were significantly associated with favorable survival outcomes in LUAD.
  • Distinct LUAD subtypes were identified with varying PCD pathway activation and immune cell infiltration.
  • Subtypes with higher cytotoxic lymphocytes and dendritic cells showed improved survival and immunotherapy potential.
  • These subtypes demonstrated increased sensitivity to targeted therapies and immune checkpoint inhibitors.

Conclusions:

  • PCD pathways, particularly ferroptosis and pyroptosis, are crucial regulators of LUAD heterogeneity and anti-tumor immunity.
  • Targeting PCD pathways offers potential for personalized treatment strategies to overcome drug resistance and enhance immunotherapy efficacy in LUAD.
  • Understanding the interplay between PCD and the tumor microenvironment is vital for developing adaptable cancer therapies.
Keywords:
Drug resistanceImmune infiltrationLung adenocarcinomaProgrammed cell deathSingle-cell RNA sequencingTherapeutic targetsTumor heterogeneity

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...